ID DDR2_MOUSE Reviewed; 854 AA. AC Q62371; B2RSD7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1997, sequence version 2. DT 24-JAN-2024, entry version 205. DE RecName: Full=Discoidin domain-containing receptor 2; DE Short=Discoidin domain receptor 2; DE EC=2.7.10.1; DE AltName: Full=CD167 antigen-like family member B; DE AltName: Full=Neurotrophic tyrosine kinase, receptor-related 3; DE AltName: Full=Receptor protein-tyrosine kinase TKT; DE AltName: Full=Tyrosine-protein kinase TYRO10; DE AltName: CD_antigen=CD167b; DE Flags: Precursor; GN Name=Ddr2; Synonyms=Ntrkr3, Tkt, Tyro10; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=8247548; RA Karn T., Holtrich U., Braeuninger A., Boehme B., Wolf G., RA Ruebsamen-Waigmann H., Strebhardt K.; RT "Structure, expression and chromosomal mapping of TKT from man and mouse: a RT new subclass of receptor tyrosine kinases with a factor VIII-like domain."; RL Oncogene 8:3433-3440(1993). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RC STRAIN=C57BL/6J; TISSUE=Brain; RX PubMed=8108131; RA Lai C., Lemke G.E.; RT "Structure and expression of the Tyro 10 receptor tyrosine kinase."; RL Oncogene 9:877-883(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Embryo; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP DISRUPTION PHENOTYPE, FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=11375938; DOI=10.1093/embo-reports/kve094; RA Labrador J.P., Azcoitia V., Tuckermann J., Lin C., Olaso E., Manes S., RA Bruckner K., Goergen J.L., Lemke G., Yancopoulos G., Angel P., Martinez C., RA Klein R.; RT "The collagen receptor DDR2 regulates proliferation and its elimination RT leads to dwarfism."; RL EMBO Rep. 2:446-452(2001). RN [5] RP FUNCTION. RX PubMed=11723120; DOI=10.1074/jbc.m107571200; RA Olaso E., Labrador J.-P., Wang L., Ikeda K., Eng F.J., Klein R., RA Lovett D.H., Lin H.C., Friedman S.L.; RT "Discoidin domain receptor 2 regulates fibroblast proliferation and RT migration through the extracellular matrix in association with RT transcriptional activation of matrix metalloproteinase-2."; RL J. Biol. Chem. 277:3606-3613(2002). RN [6] RP FUNCTION, INTERACTION WITH SRC AND SHC1, MUTAGENESIS OF TYR-471 AND RP LYS-608, AND PHOSPHORYLATION AT TYR-471. RX PubMed=11884411; DOI=10.1074/jbc.m201078200; RA Ikeda K., Wang L.H., Torres R., Zhao H., Olaso E., Eng F.J., Labrador P., RA Klein R., Lovett D., Yancopoulos G.D., Friedman S.L., Lin H.C.; RT "Discoidin domain receptor 2 interacts with Src and Shc following its RT activation by type I collagen."; RL J. Biol. Chem. 277:19206-19212(2002). RN [7] RP FUNCTION IN UP-REGULATION OF MMP13. RX PubMed=15509586; DOI=10.1074/jbc.m411036200; RA Xu L., Peng H., Wu D., Hu K., Goldring M.B., Olsen B.R., Li Y.; RT "Activation of the discoidin domain receptor 2 induces expression of matrix RT metalloproteinase 13 associated with osteoarthritis in mice."; RL J. Biol. Chem. 280:548-555(2005). RN [8] RP INVOLVEMENT IN SLI, AND TISSUE SPECIFICITY. RX PubMed=18483174; DOI=10.1210/me.2007-0310; RA Kano K., Marin de Evsikova C., Young J., Wnek C., Maddatu T.P., RA Nishina P.M., Naggert J.K.; RT "A novel dwarfism with gonadal dysfunction due to loss-of-function allele RT of the collagen receptor gene, Ddr2, in the mouse."; RL Mol. Endocrinol. 22:1866-1880(2008). RN [9] RP INVOLVEMENT IN SLI, FUNCTION, AND TISSUE SPECIFICITY. RX PubMed=19681157; DOI=10.1002/mrd.21093; RA Kano K., Kitamura A., Matsuwaki T., Morimatsu M., Naito K.; RT "Discoidin domain receptor 2 (DDR2) is required for maintenance of RT spermatogenesis in male mice."; RL Mol. Reprod. Dev. 77:29-37(2010). CC -!- FUNCTION: Tyrosine kinase that functions as a cell surface receptor for CC fibrillar collagen and regulates cell differentiation, remodeling of CC the extracellular matrix, cell migration and cell proliferation. CC Required for normal bone development. Regulates osteoblast CC differentiation and chondrocyte maturation via a signaling pathway that CC involves MAP kinases and leads to the activation of the transcription CC factor RUNX2. Regulates remodeling of the extracellular matrix by up- CC regulation of the collagenases MMP1, MMP2 and MMP13, and thereby CC facilitates cell migration and tumor cell invasion. Promotes fibroblast CC migration and proliferation, and thereby contributes to cutaneous wound CC healing. {ECO:0000269|PubMed:11375938, ECO:0000269|PubMed:11723120, CC ECO:0000269|PubMed:11884411, ECO:0000269|PubMed:15509586, CC ECO:0000269|PubMed:19681157}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl- CC [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- ACTIVITY REGULATION: Present in an inactive state in the absence of CC collagen binding and phosphorylation by SRC. Tyrosine phosphorylation CC enhances the affinity for ATP and the catalytic activity. CC -!- SUBUNIT: Binds hydroxyproline-rich sequence motifs in fibrillar, CC glycosylated collagen, such as the GQOGVMGFO motif, where O stands for CC hydroxyproline. Interacts with SRC. Interacts (tyrosine phosphorylated) CC with SHC1. {ECO:0000269|PubMed:11884411}. CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. CC -!- TISSUE SPECIFICITY: Widely expressed. Detected in lung, ovary, skin and CC in testis Leydig cells (at protein level). Widely expressed. Detected CC at high levels in heart, lung, skeletal muscle, central nervous system CC (CNS) and kidney, and at lower levels in brain and testis. Detected in CC chondrocytes in tibia growth plates of young mice. CC {ECO:0000269|PubMed:11375938, ECO:0000269|PubMed:18483174, CC ECO:0000269|PubMed:19681157}. CC -!- INDUCTION: Up-regulated during osteoblast differentiation (in vitro). CC Up-regulated in cartilage from mice with osteoarthritis. CC -!- PTM: N-glycosylated. {ECO:0000250}. CC -!- PTM: Tyrosine phosphorylated in response to collagen binding. CC Phosphorylated by SRC; this is required for activation and subsequent CC autophosphorylation on additional tyrosine residues (By similarity). CC {ECO:0000250}. CC -!- DISEASE: Note=Defects in Ddr2 are the cause of the smallie (sli) CC phenotype. Smallie mice show distinct dwarfing, with reduced body mass CC and reduced bone mineral content. Mice also have mild craniofacial CC deformities, such as protuberant eyes and snub noses. Smallie mice have CC a reduced life span, with about half of them dying within 6 months. CC Matings between male and female smallie mice do not yield any CC offspring. The levels of circulating steroid hormones remain at a level CC corresponding to prepubertal wild-type mice. Adult testes exhibit much CC reduced numbers of spermatids with atrophy of spermatogonia, Sertoli CC and Leydig cells. Ovaries show an absence of corpora lutea. CC -!- DISRUPTION PHENOTYPE: Mice are born at the expected Mendelian rate, but CC fail to thrive, resulting in much reduced adult body weight and CC dwarfing. They exhibit shortening of long bones, irregular growth of CC flat bones and a shortened snout. Young mice show shortened growth CC plates in long bones and impaired chondrocyte proliferation. Likewise, CC cultured fibroblasts from mutant mice show reduced proliferation. CC {ECO:0000269|PubMed:11375938}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: According to PubMed:18483174 Ddr2 is required for male and CC female fertility, since smallie mice with a 150 kb deletion that CC extends into the Ddr2 gene are sterile. Smallie males have defects in CC spermatogenesis (PubMed:19681157). On the other hand, the fertility CC status of mice with a targeted disruption of the Ddr2 gene has not been CC mentioned (PubMed:11375938). Thus, the infertility of smallie mice may CC be due to some additional, not yet identified defect. CC {ECO:0000305|PubMed:11375938, ECO:0000305|PubMed:19681157}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA54040.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X76505; CAA54040.1; ALT_INIT; mRNA. DR EMBL; BC138826; AAI38827.1; -; mRNA. DR EMBL; BC138827; AAI38828.1; -; mRNA. DR CCDS; CCDS48436.1; -. DR PIR; I48859; I48859. DR RefSeq; NP_072075.2; NM_022563.2. DR RefSeq; XP_006496759.1; XM_006496696.3. DR RefSeq; XP_006496760.1; XM_006496697.3. DR RefSeq; XP_006496761.1; XM_006496698.3. DR AlphaFoldDB; Q62371; -. DR SMR; Q62371; -. DR BioGRID; 201871; 2. DR STRING; 10090.ENSMUSP00000141443; -. DR GlyCosmos; Q62371; 5 sites, No reported glycans. DR GlyGen; Q62371; 5 sites. DR iPTMnet; Q62371; -. DR PhosphoSitePlus; Q62371; -. DR SwissPalm; Q62371; -. DR MaxQB; Q62371; -. DR PaxDb; 10090-ENSMUSP00000129624; -. DR PeptideAtlas; Q62371; -. DR ProteomicsDB; 277968; -. DR Pumba; Q62371; -. DR Antibodypedia; 4177; 514 antibodies from 36 providers. DR DNASU; 18214; -. DR Ensembl; ENSMUST00000027985.8; ENSMUSP00000027985.3; ENSMUSG00000026674.10. DR Ensembl; ENSMUST00000170800.8; ENSMUSP00000129624.2; ENSMUSG00000026674.10. DR Ensembl; ENSMUST00000194690.6; ENSMUSP00000141443.2; ENSMUSG00000026674.10. DR GeneID; 18214; -. DR KEGG; mmu:18214; -. DR UCSC; uc007dlu.2; mouse. DR AGR; MGI:1345277; -. DR CTD; 4921; -. DR MGI; MGI:1345277; Ddr2. DR VEuPathDB; HostDB:ENSMUSG00000026674; -. DR eggNOG; KOG1094; Eukaryota. DR GeneTree; ENSGT00940000154842; -. DR HOGENOM; CLU_008873_2_0_1; -. DR InParanoid; Q62371; -. DR OMA; HEPPNSC; -. DR OrthoDB; 2999496at2759; -. DR PhylomeDB; Q62371; -. DR TreeFam; TF317840; -. DR BRENDA; 2.7.10.1; 3474. DR Reactome; R-MMU-3000171; Non-integrin membrane-ECM interactions. DR BioGRID-ORCS; 18214; 2 hits in 80 CRISPR screens. DR ChiTaRS; Ddr2; mouse. DR PRO; PR:Q62371; -. DR Proteomes; UP000000589; Chromosome 1. DR RNAct; Q62371; Protein. DR Bgee; ENSMUSG00000026674; Expressed in vault of skull and 239 other cell types or tissues. DR ExpressionAtlas; Q62371; baseline and differential. DR GO; GO:0015629; C:actin cytoskeleton; ISO:MGI. DR GO; GO:0016324; C:apical plasma membrane; ISO:MGI. DR GO; GO:0005886; C:plasma membrane; ISO:MGI. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005518; F:collagen binding; IDA:MGI. DR GO; GO:0038062; F:protein tyrosine kinase collagen receptor activity; IDA:UniProtKB. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0031214; P:biomineral tissue development; IMP:UniProtKB. DR GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl. DR GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl. DR GO; GO:0035988; P:chondrocyte proliferation; IMP:UniProtKB. DR GO; GO:0030199; P:collagen fibril organization; IMP:UniProtKB. DR GO; GO:0038063; P:collagen-activated tyrosine kinase receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0003416; P:endochondral bone growth; IMP:UniProtKB. DR GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI. DR GO; GO:1901299; P:negative regulation of hydrogen peroxide-mediated programmed cell death; ISO:MGI. DR GO; GO:0001503; P:ossification; IEA:UniProtKB-KW. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:MGI. DR GO; GO:0032967; P:positive regulation of collagen biosynthetic process; ISO:MGI. DR GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; ISS:UniProtKB. DR GO; GO:0090091; P:positive regulation of extracellular matrix disassembly; IMP:UniProtKB. DR GO; GO:0010763; P:positive regulation of fibroblast migration; IMP:UniProtKB. DR GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:UniProtKB. DR GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; ISO:MGI. DR GO; GO:2000491; P:positive regulation of hepatic stellate cell activation; ISO:MGI. DR GO; GO:1904899; P:positive regulation of hepatic stellate cell proliferation; ISO:MGI. DR GO; GO:0010976; P:positive regulation of neuron projection development; IBA:GO_Central. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0045860; P:positive regulation of protein kinase activity; ISS:UniProtKB. DR GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; ISO:MGI. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; ISO:MGI. DR GO; GO:0090303; P:positive regulation of wound healing; ISO:MGI. DR GO; GO:0030500; P:regulation of bone mineralization; ISS:UniProtKB. DR GO; GO:0034103; P:regulation of tissue remodeling; ISO:MGI. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:MGI. DR CDD; cd00057; FA58C; 1. DR Gene3D; 2.60.120.1190; -; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR048525; DDR1-2_DS-like. DR InterPro; IPR000421; FA58C. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF295; DISCOIDIN DOMAIN-CONTAINING RECEPTOR 2; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF21114; DDR1-2_DS-like; 1. DR Pfam; PF00754; F5_F8_type_C; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00231; FA58C; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01285; FA58C_1; 1. DR PROSITE; PS01286; FA58C_2; 1. DR PROSITE; PS50022; FA58C_3; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. DR Genevisible; Q62371; MM. PE 1: Evidence at protein level; KW ATP-binding; Cell membrane; Disulfide bond; Glycoprotein; Kinase; Membrane; KW Nucleotide-binding; Osteogenesis; Phosphoprotein; Receptor; KW Reference proteome; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..21 FT /evidence="ECO:0000255" FT CHAIN 22..854 FT /note="Discoidin domain-containing receptor 2" FT /id="PRO_0000016747" FT TOPO_DOM 22..399 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 400..421 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 422..854 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 30..185 FT /note="F5/8 type C" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00081" FT DOMAIN 563..848 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 452..471 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 709 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 569..577 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 608 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 471 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000269|PubMed:11884411" FT MOD_RES 735 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q16832" FT MOD_RES 739 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q16832" FT MOD_RES 740 FT /note="Phosphotyrosine; by SRC and autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q16832" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 213 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 261 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 372 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 30..185 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00081" FT DISULFID 73..177 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00081" FT MUTAGEN 471 FT /note="Y->F: Reduces tyrosine phosphorylation by 90%; when FT associated with E-608." FT /evidence="ECO:0000269|PubMed:11884411" FT MUTAGEN 608 FT /note="K->E: Abolishes kinase activity. Reduces tyrosine FT phosphorylation by 90%; when associated with F-471." FT /evidence="ECO:0000269|PubMed:11884411" SQ SEQUENCE 854 AA; 96482 MW; 45CFD2BE9ED524D4 CRC64; MIPIPRMPLV LLLLLLILGS AKAQVNPAIC RYPLGMSGGH IPDEDITASS QWSESTAAKY GRLDSEEGDG AWCPEIPVQP DDLKEFLQID LRTLHFITLV GTQGRHAGGH GIEFAPMYKI NYSRDGSRWI SWRNRHGKQV LDGNSNPYDV FLKDLEPPIV ARFVRLIPVT DHSMNVCMRV ELYGCVWLDG LVSYNAPAGQ QFVLPGGSII YLNDSVYDGA VGYSMTEGLG QLTDGVSGLD DFTQTHEYHV WPGYDYVGWR NESATNGFIE IMFEFDRIRN FTTMKVHCNN MFAKGVKIFK EVQCYFRSEA SEWEPTAVYF PLVLDDVNPS ARFVTVPLHH RMASAIKCQY HFADTWMMFS EITFQSDAAM YNNSGALPTS PMAPTTYDPM LKVDDSNTRI LIGCLVAIIF ILLAIIVIIL WRQFWQKMLE KASRRMLDDE MTVSLSLPSE SSMFNNNRSS SPSEQESNST YDRIFPLRPD YQEPSRLIRK LPEFAPGEEE SGCSGVVKPA QPNGPEGVPH YAEADIVNLQ GVTGGNTYCV PAVTMDLLSG KDVAVEEFPR KLLAFKEKLG EGQFGEVHLC EVEGMEKFKD KDFALDVSAN QPVLVAVKML RADANKNARN DFLKEIKIMS RLKDPNIIRL LAVCITEDPL CMITEYMENG DLNQFLSRHE PLSSCSSDAT VSYANLKFMA TQIASGMKYL SSLNFVHRDL ATRNCLVGKN YTIKIADFGM SRNLYSGDYY RIQGRAVLPI RWMSWESILL GKFTTASDVW AFGVTLWETF TFCQEQPYSQ LSDEQVIENT GEFFRDQGRQ IYLPQPALCP DSVYKLMLSC WRRETKHRPS FQEIHLLLLQ QGAE //